The Correlation of Tau Levels with Blood Monocyte Count in Patients with Alzheimer's Disease
- PMID: 34924377
- DOI: 10.3233/JAD-210692
The Correlation of Tau Levels with Blood Monocyte Count in Patients with Alzheimer's Disease
Abstract
Background: Recent studies have shown that monocytes can phagocytize the tau protein, which may ameliorate tau-type pathology in Alzheimer's disease (AD). However, there are few clinical studies on the relationship between monocytes and tau-type pathology in AD patients.
Objective: We aimed to explore changes in peripheral monocytes and their association with tau protein in AD patients.
Methods: A total of 127 clinically diagnosed AD patients and 100 age- and sex-matched cognitively normal controls were recruited for analysis of the correlation of plasma tau levels with the blood monocyte count. Cerebrospinal fluid (CSF) samples from 46 AD patients and 88 controls were further collected to analyze the correlation of CSF tau and amyloid-β (Aβ) levels with the blood monocyte count. 105 clinically diagnosed mild cognitive impairment (MCI) patients and 149 age- and sex-matched cognitively normal controls were recruited from another cohort for verification.
Results: Compared to normal controls, AD patients showed a significant reduction in the blood monocyte count. In addition, the monocyte count of AD patients was negatively correlated with CSF t-tau and p-tau levels but not with plasma tau levels. In normal people, monocyte count lack correlation with tau levels both in plasma and CSF. Monocyte count were not correlated with CSF Aβ levels in either group but were negatively correlated with CSF tau/Aβ42 levels in the AD group. We had further verified the correlations of monocyte count with CSF tau levels in another cohort.
Conclusion: This study suggests that monocytes may play an important role in the clearance of tau protein in the brain.
Keywords: Alzheimer’s disease; monocytes; pathogenesis; tau.
Similar articles
-
Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.J Alzheimers Dis. 2015;44(2):525-39. doi: 10.3233/JAD-141725. J Alzheimers Dis. 2015. PMID: 25391385
-
Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid.Bipolar Disord. 2016 Feb;18(1):63-70. doi: 10.1111/bdi.12360. Epub 2016 Feb 15. Bipolar Disord. 2016. PMID: 26876913
-
Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.J Neurosci. 2019 Sep 11;39(37):7428-7437. doi: 10.1523/JNEUROSCI.1056-19.2019. Epub 2019 Jul 26. J Neurosci. 2019. PMID: 31350262 Free PMC article.
-
Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.Methods. 2012 Apr;56(4):484-93. doi: 10.1016/j.ymeth.2012.03.023. Epub 2012 Apr 6. Methods. 2012. PMID: 22503777 Review.
-
Amyloid beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: a review of recent literature.Curr Clin Pharmacol. 2008 May;3(2):123-31. doi: 10.2174/157488408784293723. Curr Clin Pharmacol. 2008. PMID: 18700307 Review.
Cited by
-
Integrating peripheral blood and brain transcriptomics to identify immunological features associated with Alzheimer's disease in mild cognitive impairment patients.Front Immunol. 2022 Sep 9;13:986346. doi: 10.3389/fimmu.2022.986346. eCollection 2022. Front Immunol. 2022. PMID: 36159817 Free PMC article.
-
Association of Peripheral Blood Cell Profile With Alzheimer's Disease: A Meta-Analysis.Front Aging Neurosci. 2022 May 6;14:888946. doi: 10.3389/fnagi.2022.888946. eCollection 2022. Front Aging Neurosci. 2022. PMID: 35601620 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
